WyBioLogics and HK Innoen Complete Patent Application for Jointly Developed HLA-G Antibody

[Asia Economy Reporter Lee Gwan-joo] Y-Biologics announced on the 14th that it has completed a domestic patent application for the immune-oncology candidate HLA-G monoclonal antibody, which it has been jointly researching with HK Innoen.

HLA-G is an immune checkpoint protein expressed in various cancer types and is attracting attention as an alternative target for tumors that show little response to existing anti-PD-(L)1 inhibitors.

HK Innoen plans to expand follow-up research to develop not only antibody therapeutics but also CAR-T and CAR-NK cell therapies using the HLA-G antibody developed through joint research with Y-Biologics. Y-Biologics aims to continue developing next-generation bispecific antibody immune-oncology drugs that simultaneously target HLA-G and the CD3 of T cells.

Y-Biologics explained, “By developing therapeutics that meet the demand for new immune-oncology biomarkers, we expect to improve treatment efficacy even in solid tumors,” adding, “This will replace the unmet needs caused by low survival rates, side effects, and non-responsiveness of existing chemotherapy and targeted cancer therapies.”